ALCLS:EPA
Cellectis SA
€1.50
arrow_downward
-42.86%(-1.13) 1D
Sep 14, 5:38:34 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALCLS...
Open
€1.76
High
€1.79
Low
€1.44
Mkt. cap
108.78M
Avg. vol.
126.41K
Volume
1.36M
52-wk high
€4.84
52-wk low
€1.44
EPS
-€0.56
Shares outstanding
72.09M
No. of employees
227
Open
€1.76
High
€1.79
Low
€1.44
Mkt. cap
108.78M
Avg. vol.
126.41K
Volume
1.36M
52-wk high
€4.84
52-wk low
€1.44
EPS
-€0.56
Shares outstanding
72.09M
No. of employees
227
News stories
From web sources and news partners
www.marketscreener.com
·
3 hours ago
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company And Advances .HEAL-101 And .HEAL-201 Programs
Pharmaceutical Executive
·
3 hours ago
Cellectis Transforming Into In Vivo Gene Editing Company
TradingView
·
4 hours ago
ALCLS: Pivot to in vivo gene editing with two lead programs, extended runway, and ongoing partnerships
Benzinga
·
5 hours ago
Nasdaq Down Over 200 Points; Cellectis Shares Plunge
Profile
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
About Cellectis SA